Skip to main content
main-content

Genitourinary cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews top story

CASPIAN: Durvalumab addition boosts SCLC survival

IV drip 2

Adding durvalumab to first-line chemotherapy significantly improves the overall survival of patients with extensive-stage small-cell lung cancer, a phase III trial shows.

medwireNews top story

Early data show promise for the FGFR inhibitor rogaratinib

Pills in hand

The FGFR inhibitor rogaratinib is well tolerated and clinically active in patients with various tumor types selected for treatment on the basis of FGFR mRNA overexpression, phase I study data show.

medwireNews top story

Meta-analysis supports MRI plus targeted biopsy for prostate cancer diagnosis

Man in scanner

Prebiopsy multiparametric magnetic resonance imaging plus targeted biopsy is associated with increased detection of clinically significant prostate cancer versus ultrasonography-guided systematic biopsy alone, study data show.

medwireNews top story

HIV infection associated with worse prostate cancer outcomes

Blood samples_HIV+

Older individuals with HIV and prostate cancer have worse outcomes than corresponding cancer patients without HIV, according to a large database study from the USA.

Expert video interview

Adjuvant chemotherapy for upper tract urothelial cancer

(Neo)adjuvant therapy for upper tract urothelial cancer (video)

Dr Alison Birtle (Rosemere Cancer Centre, Royal Preston Hospital, UK) discusses the rationale for adjuvant chemotherapy for upper tract urothelial cancer (UTUC), the POUT trial and its practice-changing implications for treatment of UTUC.

Expert opinion

Bipolar androgen therapy: Progress and future directions

Bipolar androgen therapy: Progress and future directions

Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.

Expert opinion

Urinary biomarkers in the management of prostate cancer

Urinary biomarkers in the management of prostate cancer

Non-invasive biomarkers have the potential to guide and improve prostate cancer management in many ways. Maria Frantzi, Agnieszka Latosinska, and Harald Mischak (Mosaiques Diagnostics GmbH, Germany) outline some promising markers and what is needed to implement them in the clinic.

17-06-2019 | Prostate cancer | Video | Article

MRI-targeted biopsy for prostate cancer diagnosis

Veeru Kasivisvanathan explains the background and clinical implications of the PRECISION trial, which tested whether using multiparametric MRI with a targeted biopsy was noninferior to standard transrectal ultrasonography–guided biopsy in the detection of clinically significant prostate cancer.

12-06-2019 | Urothelial cancer | ASCO 2019 | Article

Expert comment: Phase II trial of enfortumab vedotin in urothelial cancer

ASCO expert Robert Dreicer gives his quick take on why the enfortumab vedotin data reported at the meeting hold so much promise for advanced urothelial carcinoma patients who have progressed on prior therapy (1:25).

12-06-2019 | Urothelial cancer | ASCO 2019 | Article

Researcher comment: Enfortumab vedotin active in advanced urothelial carcinoma

Investigator Daniel Petrylak summarizes the key results of the phase II EV-201 trial of the antibody–drug conjugate enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer (2:42).

04-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | Article

Expert comment: ENZAMET and TITAN trials

Earle Burgess provides an independent commentary on the ENZAMET and TITAN results presented at the 2019 ASCO Annual Meeting, and discusses what these data mean for patients and physicians (2:57).

04-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | Article

Researcher comment: OS boost with enzalutamide in metastatic CSPC setting

Christopher Sweeney presents the main findings of the ENZAMET trial, which evaluated the impact of supplementing androgen deprivation therapy with enzalutamide in men with advanced castration-sensitive prostate cancer (3:10).

01-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | Article

Researcher comment: Apalutamide addition improves metastatic CSPC survival

Study author Axel Merseburger takes us through the TITAN trial investigating the addition of apalutamide to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting, and also addresses the key question of how physicians should choose between the available treatment options (3:03).

05-09-2019 | Testicular cancer | News

Brain metastases linked to poor survival in men with testicular germ cell tumors

Among men with testicular germ cell tumors, those with more than one extrapulmonary metastasis – particularly brain metastases – have the poorest survival, according to an analysis of data the US SEER database.

04-09-2019 | Prostate cancer | News

Pre-existing CVD linked to increased mortality with abiraterone, enzalutamide

Elderly patients with prostate cancer and pre-existing cardiovascular disease have a significantly higher short-term mortality risk following abiraterone acetate or enzalutamide treatment than those without CVD, US study findings indicate.

02-09-2019 | Cardiovascular disease | Highlight | News

Elevated cardiovascular risk seen in survivors of most common cancers

Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.

Our Editorial Board advisor

Axel S Merseburger MD

Dr Merseburger is currently Professor and Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, having previously served as Vice Chairman of the Department of Urologic Oncology and Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Dr Merseburger’s key areas of interest are renal cell carcinoma, prostate cancer and transitional cell carcinoma, with special attention given to novel markers and prognostic factors. He is a principal investigator in German Phase II and III trials.

Expert opinion

Bipolar androgen therapy: Progress and future directions

Bipolar androgen therapy: Progress and future directions

Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.

Journal articles and book chapters

26-03-2019 | Prostate cancer | Article

The role of multiparametric MRI in biopsy-naive prostate cancer

Lebastchi Ah, Pinto PA. Nat Rev Urol 2019; 16: 276–277. doi:10.1038/s41585-019-0173-7 

21-08-2018 | Prostate cancer | Article

Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations

Crawford ED, Heidenreich A, Lawrentschuk N et al. Prostate Cancer Prostatic Dis 2018. doi:10.1038/s41391-018-0079-0.

29-06-2018 | Castration-resistant prostate cancer | Article

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Hussain M et al. N Engl J Med 2018; 378(26): 2465-2474. doi:10.1056/NEJMoa1800536

28-06-2018 | PARP inhibitors | Article

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

Ashworth A. Lord CJ. Nat Rev Clin Oncol 2018. doi:10.1038/s41571-018-0055-6

14-06-2018 | Renal cell carcinoma | Article

An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma

Grünwald V et al. Nat Rev Urol 2018. doi:10.1038/s41585-018-0034-9.

05-06-2018 | Prostate cancer | Article

Statin use and time to progression in men on active surveillance for prostate cancer

Jayalath VH et al. Prostate Cancer Prostatic Dis 2018. doi:10.1038/s41391-018-0053-x

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

Images and illustrations

12-04-2018 | Prostate cancer | Images and illustration slides | Collection

Prostate cancer imaging

This downloadable powerpoint slide set presents an overview of the imaging techniques used to assess prostate cancer from initial diagnosis and staging, to evaluation of residual or recurrent disease after treatment. These slides can be used for reference purposes or for inclusion in one’s own slide sets. Source: Vargas HA et al. Prostate Cancer Imaging. In: Bach Am, Zhang J, eds. Atlas of Genitourinary Oncological Imaging. Springer New York.

Image Credits